Please ensure Javascript is enabled for purposes of website accessibility

Boston Scientific's "Challenging" Quarter

By Brian Orelli, PhD - Updated Apr 6, 2017 at 1:24PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Yeah, that's an understatement.

Boston Scientific (NYSE: BSX) fixed its paperwork problem with the Food and Drug Administration earlier this month, but the resulting recall took its toll on first-quarter profits nonetheless. The company's president and CEO, Ray Elliott, dubbed this a "challenging" quarter. Yeah, I'd call that an understatement.

The inability to sell some versions of its heart defibrillators for a couple of weeks cost the company $72 million in revenue last quarter. It'll cut into second-quarter revenue as well, because Boston Scientific didn't get an OK from the FDA to start selling the products again until the middle of this month. As a result, the company reduced its revenue guidance by $500 million.

But the long-term effect should have investors truly worried. Will doctors trust the company after its mistake? Sure, this wasn't a quality issue. But if a company can't file the proper paperwork with the FDA, will doctors feel confident implanting its devices in patients? Taking the things out isn't very easy, you know.

All told, Boston Scientific says it lost 8 percentage points of market share to rivals St. Jude Medical (NYSE: STJ) and Medtronic (NYSE: MDT) last quarter, and it expects to lose another four points in the second quarter. The company expects to pare that 12-point loss in market share down to just five points by year end, but that's just optimism, as far as I can tell.

While the company is wooing back electrophysiologists, what will happen to its other major segment, drug-eluting stents? Sales of the tiny mesh devices were down 9% in the first quarter, and down 12% on a constant currency basis. Sales could slip further if Medtronic, Abbott Labs (NYSE: ABT), and Johnson & Johnson (NYSE: JNJ) decide to make a push in the segment while management is distracted.

Might Boston Scientific be a bad-news buy? Sure, the company could turn things around, and shareholders and management could live happily ever after. But, sometimes past performance does indicate future returns. Until management demonstrates a track record of success, I'm staying far away.

Johnson & Johnson is a Motley Fool Income Investor selection. Motley Fool Options has recommended buying calls on Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool owns shares of and has written puts on Medtronic. The Fool's disclosure policy is a good value, especially considering its free price.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Boston Scientific Corporation Stock Quote
Boston Scientific Corporation
$41.03 (0.15%) $0.06
Johnson & Johnson Stock Quote
Johnson & Johnson
$170.18 (-0.01%) $0.02
Medtronic plc Stock Quote
Medtronic plc
$93.10 (-0.51%) $0.48
St. Jude Medical, Inc. Stock Quote
St. Jude Medical, Inc.
Abbott Laboratories Stock Quote
Abbott Laboratories
$107.91 (-1.00%) $-1.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/10/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.